<DOC>
	<DOC>NCT01673919</DOC>
	<brief_summary>This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.</brief_summary>
	<brief_title>A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>Patients who completed visit 33 (week 104) of WA19977 study and who may benefit from study drug treatment according to the investigator's assessment Patients have to receive the first RoActemra/Actemra infusion in this study at the Week 8 visit at the latest Females of childbearing potential and males with female partners of childbearing potential must agree to use effective contraception as defined by protocol Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977 Treatment with any investigational agent since the last administration of study drug in the core study WA19977 Patient developed any other autoimmune rheumatic disease or overlap syndrome other than the permitted polyarticularcourse Juvenile Idiopathic Arthritis (JIA) subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug Any significant concomitant disease or medical or surgical condition History of significant allergic or infusion reactions to prior biologic therapy Currently active primary or secondary immunodeficiency Any infections with contraindications to RoActemra/Actemra therapy according to investigator judgment Inadequate hepatic, renal or bone marrow function</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>